LAUSR

Age‐related macular degeneration (AMD) is a major cause of visual impairment and severe vision loss worldwide, while the currently available treatments are often unsatisfactory. Previous studies have demonstrated both inflammation and oxidative‐stress‐induced damage to the retinal pigment epithelium are involved in the pathogenesis of aberrant development of blood vessels in wet AMD (wet‐AMD). Although antivascular endothelial growth factor (VEGF) therapy (e.g., Ranibizumab) can impair the growth of new blood vessels, side effects are still found with repeated monthly intravitreal injections. Here, an injectable antibody‐loaded supramolecular nanofiber hydrogel is fabricated by simply mixing betamethasone phosphate (BetP), a clinic anti‐inflammatory drug, anti‐VEGF, the gold‐standard anti‐VEGF drug for AMD treatment, with CaCl2. Upon intravitreal injection, such BetP‐based hydrogel (BetP‐Gel), while enabling long‐term sustained release of anti‐VEGF to inhibit vascular proliferation in the retina and attenuate choroidal neovascularization, can also scavenge reactive oxygen species to reduce local inflammation. Remarkably, such BetP‐Gel can dramatically prolong the effective treatment time of conventional anti‐VEGF therapy. Notably, anti‐VEGF‐loaded supramolecular hydrogel based on all clinically approved agents may be readily translated into clinical use for AMD treatment, with the potential to replace the current anti‐VEGF therapy.